DRUG POISONRELATED PULMONARY FIBROSIS

Pandhare Shubham .D, Jadhav Pallavi .T,

Student, Teacher
Pratibhatai Pawar College Of Pharmacy

Abstract:
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosis lung disease limited to the lungs and associated with the histologic appearance of usual interstitial pneumonia (UIP) on surgical lung biopsy.Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,progressive scarring of the lungs and the pathological hallmark of usual interstitial pneumonia. Current paradigms suggest alveolar epithelial cell damage is a key initiating factor. Globally, incidence of the disease is rising, with associated high morbidity, mortality, and economic healthcare burden. Diagnosis relies on a multidisciplinary team approach with exclusion of other causes of interstitial lung disease.Pulmonary fibrosis occurs in a variety of clinical settings, constitutes a major cause of morbidity and mortality, and represents an enormous unmet medical need. However, the disease is heterogeneous, and the failure to accurately discern between forms of fibro sing lung diseases leads to inaccurate treatments. Pulmonary fibrosis occurring in the context of connective tissue diseases is often characterized by a distinct pattern of tissue pathology and may be amenable to immunosuppressive therapies.

Keywords: Idiopathic pulmonary fibrosis, interstitial lung disease, interstitial pneumonia, Connective tissue, Immunosuppressive therapies,

Introduction:
The Poisoning is a common cause of accidental death and injury in India, accounting for 1, 61,819 deaths between the 2011 and 2015. Drugs of abuse include 9 classes of substances alcohol, opioids, cannabinoids, sedative-hypnotics, cocaine, and stimulants consisting of caffeine, hallucinogens, tobacco, and risky solvents. [1] The source of medication poisoning varies by region and country, which reflect the prescribing practice and the supply of medication in the population. [2]Pulmonary fibrosis is a chronic fibro sing lung disease limited to the lungs and associated with the histological appearance of usual interstitial pneumonia. [3] Connective tissue diseases such as rheumatoid arthritis and systemic sclerosis (scleroderma) generally are accompanied by pulmonary fibrosis, and the analysis can often be established with reasonable confidence. [4] The path physiological basis of IPF has been the subject of much debate over the last few decades. [5] Symptoms embrace shortness of breath, a dry cough, feeling tired, weight loss, and nail symptom. Complications could embrace respiratory organ hypertension; metabolic process failure. [6] Autophagic death differs from apoptotic cell-death; the previous doesn't involve turtle activation None the less, the 2 processes will exist. [7] This text can describe the progressive nature of IPF and also the utility of anti fibrotic therapies, with a spotlight on the importance of early treatment. [8]The presence of a usual respiratory disease pattern on high-resolution X-raying in patients not subjected to, and specific combos of HRCT and SLB patterns in patients subjected to SLB. [9] The causes of IPF stay unknown, though it's thought to result from a mixture of genetic and environmental factors. [10]Respiratory organ pathology comprise a large array of respiratory organ diseases that are usually confusing to internal medicine and respiratory organ physicians alike. [11]Careful clinical investigation aims to move from these inexact terms to the diagnosing of a particular illness. [12] Risk factors for progression embody older age, male sex, lower baseline respiratory organ operate, and picture taking honeycombing or usual respiratory disorder (UIP) pattern of injury. [13]

Pulmonary fibrosis:
Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitial. Interstitial lung diseases (ILDs) encompass a large and heterogeneous group of disorders, a number of which are characterized by progressive pulmonary fibrosis that leads to respiratory failure and death. [14] The Pulmonary fibrosis is a group of chronic, irreversible, and fatal interstitial lung diseases that occur mostly in middle- aged and elderly people. [15]Unfortunately, the pathogenesis of pulmonary fibrosis is still poorly under-stood and there are no effective therapeutic drugs [16].The for most common class of pulmonary fibrosis is disorder idiopathic pulmonary fibrosis (IPF). The median survival for IPF is only 2 year to 4 years. [17]



Figure 1: Pathogenesis of pulmonary fibrosis. [18]

The function for proinflammatory mediators in PF (pulmonary fibrosis)

Usual respiratory disorder (UIP) is that the classic pathologic description of IPF. UIP is characterized by areas of traditional respiratory organ intermixed with varied staged destruction of the opening house. This temporal heterogeneousness with fibroblastic foci is that the hallmark. Note that this description doesn't embrace nor need the presence of associate degree inflammatory cellular infiltrate [19]Nonspecific respiratory disorder has additional pathologic inflammation and, once seen in diagnostic assay samples, will have an effect on prognosis. [20]TNF can inhibit collagen synthesis in my fibroblasts, TNF antagonists might have the undesired effect of worsening the disease. [21]



Figure 2. Proinflammatory and profibrotic mediators in the initiation and maintenance of fibrosis. [22]

Mechanism of pulmonary fibrosis:

IPF, and such treatment choices are not t to any extent further inspired as a remedy intervention for IPF. [23] Formative cell populations are liable for providing structure to organs, thus is so a vital a part of the repair method following harm. [24] Though long related to progressive respiratory organ pathology. [25]Pulmonary pathology could be a respiratory organ unwellness that's refractory to treatment and carries a high fatality rate. [26]Several mechanisms are incontestable to play a task within the pathology insurrection and progression; nonetheless, the trail physiology of fibrotic processes continues to be incompletely

outlined. [27] Respiratory organ my fibroblasts will originate from completely different sources and their fate is necrobiosis permitting the termination of the healing method. [28]



Figure: 3 Schematic diagram representing three broad mechanisms (inflammation, oxidative stress, and coagulation disturbances) that alone or in combination may be responsible for alterations in mesenchymal cells, epithelial cells, and extracellular matrix that result in pulmonary fibrosis following lung injury. [29]

Pathogenesis of pulmonary fibrosis:

Understanding the etiology of pulmonary fibrosis will give long symptomatic relief and attainable reversal of the disease. To the present finish, there are units presently many well-known risk factors related to pulmonary fibrosis that may be delineate below. [6] CF patients area unit liable to progressive pulmonary harm, sub membrane inflammation, and redoubled condition to microorganism infection. [30]This hypothesis for IPF pathological process and path physiology suggests that continual vegetative cell harm initiates and induces a deregulated repair response, and excessive accumulation of extracellular matrix secreted by my fibroblasts ends up pulmonary fibrosis. [31]These disorders seem to own variety of infective processes in common, that cause similar clinical and pathological options [32].It should be noted, however, that pulmonary fibrosis may occur within the absence of a clear-cut inciting agent and while not a clinically obvious initial acute inflammatory part. This can be called disorder IPF or cryptogenic fibrosis alveolitis. [33]

Aetiological group	Examples	
	Established	Putative
1. Infective		
bacteria	Tuberculosis	
funghi	Histoplasmosis	
viral	Measles	EBV/Hep C
4. Metabolic	Uraemia	Abnormal Ca^{2+} sensing (Hermansky–Pudlak)
5. Genetic	Familial CFA	Atopy
6. Neoplastic	Alveolar cell carcinoma	
7. Physical	Radiation	
8. Drug-related	Bleomycin Amiodarone	
9. Organic/inorganic dust inhalation	Pigeon-fanciers lung silicosis/ asbestosis	?Air pollutants
10. Autoimmune	?Rheumatoid arthritis associated fibrosis	Anti-alveolar cell antibodies in CFA
11. Circulatory/haemodynamic	Left ventricular failure/ARDS	

Table 1, Established and putative an etiological factors for pulmonary fibrosis. [34]

Clinical and pathological feature of pulmonary fibrosis:
The term ‘‘pulmonary fibrosis is employed clinically to explain many styles of diffuse opening respiratory organ diseases classified as disorder opening pneumonias with a typical hallmark of fibrosis.[35] Median survival from time of identification has been reportable as a pair of.5 to 3.5 years, with most patients dying from sickness progression to metabolism insufficiency. Ensuing studies have disclosed that there are often a variable clinical course, starting from subclinical and slowly progressive sickness to speedy acute decomposition and death. [36]

Classification pulmonary fibrosis:
The pulmonary fibrosis is the classify as follow: [37]



Therapies:
Antifibrotic therapy:
Pirfenidone and nintedanib are anti fibrotic medicine that, despite having differing modes of action, are equally effective in attenuating the speed of respiratory organ perform decline by regarding 50%. These therapies are wide thought-about to enhance lifetime, maybe by the maximum amount as 2 to 5 years. [38]

Current cell therapy:
Despite the very fact that MS medical aid has been utilized in the clinical for roughly 10 years, over 75% of studies are still in phase II clinical trial or earlier. Respiratory organ diseases account for twenty three of the 493 transplantation studies. [39]

Immunosuppression therapy:
All but two studies coverage over one patient used historical controls. Victimization such controls for controlled trials of latest interventions, instead of controls treated in parallel, is related to inflation of proof for profit. These studies thus can't be thought-about to supply sensible proof of profit or damage from immunological disorder. [40]

Lung Transplantation therapy:

Patients listed for respiratory organ transplantation are typically accepted as being those for whom no different treatment choice is out there, UN agency has a bigger than 50% probability of death among 2 years while not transplantation, and a projected surgical survival of a minimum of 5 years.[41]

Indications
High risk of death (>50%) in the following two years without transplant
High probability (>80%) of surviving at least 90 days after transplantation
High probability (>80%) of surviving 5 years after transplantation of any general medical condition
Absolute Contraindications
Recent tumor history (>5 years free of disease)
Dysfunction of another major organ
Nonvascularizable coronary disease
Hemorrhagic diathesis
Deformities of the chest wall
Morbid obesity
Tuberculosis infection
Infection by highly resistant germs without control
Severely altered functional status with inability to rehabilitate
Severe psychiatric disorders
Poor social support
Nonadherence to treatment
Relative Contraindications
Age > 65 years
Obesity (BMI 30–34.9)
Severe malnutrition
Symptomatic severe osteoporosis
Previous thoracic surgery with pulmonary resection
Mechanical ventilation and/or extracorporeal support
Infection by virus B or C with evidence of significant liver injury and/or portal hypertension

Table 2. Indications and contraindications of lung transplant. [42]

Mechanical bridges to lung transplant:

ECLS recommended:

Young age;
Absence of multiple-organ dysfunction;
Smart potential for rehabilitation.

ECLS not recommended:

Septic shock;
Multi-organ dysfunction;
Severe blood vessel occlusive disease;
Heparin-induced thrombocytopenia;
Previous prolonged mechanical ventilation;
Advanced age;
Obesity.

"Bridge to respiratory organ transplantation" refers to ways to manage with artificial support the acutely decompensating patient till an appropriate organ is accessible. [43]

Prevalence:

Incidence by Age and Sex:

Among the on 1,211 persons meeting the broad definition of IPF, 295 had fresh diagnosed sickness in CY2000. Among the 387 persons meeting the slender case definition, the corresponding figure was 120. supported the broad case definition, the annual incidence of IPF was calculable to vary from on1.2 per 100,000 persons aged eighteen to thirty four year to 76.4 per 100,000 among those aged seventy five year or older.[44] men (1•5 to 1•7:1) than in ladies and also the frequency will increase with age.[45]

Incidence in United State:
In the USA, the prevalence of IPF varied looking on the population studied and also the case definition wont to establish IPF patients: from 14 to 27.9 cases per 100,000 of the final population victimization slender case definitions and from 42.7 to sixty three cases per 100,000 populations victimization broad case definitions. [45] The fatality rate of IPF patients has been reported to be as high as 13.36 per 100000 (age-standardized rate in Northern Ireland). Most of the deaths among patients with IPF are because of metabolism failure. [47]

Risk factors:
Male sex:
Across the globe, IPF (Idiopathic pulmonary fibrosis) is additional rife in men, World Health Organization account for about 70% of all cases globally, supported information derived from national registries and international trials of IPF. [48] Sex hormones are hypothesized joined principle for the sex distinction, particularly within the bleomycin mouse model of respiratory organ pathology. This animal model of respiratory organ pathology demonstrates an analogous sexual dimorphism as ascertained in humans with male mice being additional at risk of sickness. [49] Animal models counsel that male sex hormones area unit related to accelerated pathology, [50] whereas feminine sex hormones is also protecting against pulmonary fibrosis. [51]

Genetics:
Studies of familial clump of respiratory organ pathology provided the primary clue toward a genetic condition to IPF. [52] equally, whereas the TOLLIP minor citron is protecting against the event of IPF, it's related to worse survival in established IPF.[53] whereas the minor citron of MUC5B has been postulated to account for about half-hour of the danger for developing IPF, it's additionally related to higher survival than the wild-type genotype in established IPF.[54]

Aging:
IPF patients relative to controls are reported even in those IPF patients while not mutations within the enzyme genes. on the far side abnormal end shortening, the molecular basis underlying the condition of the ageing lung to a deregulated response to lung small injury includes a ageing constitution in IPF lung fibroblasts that alters the magnitude relation of proliferation to programmed cell death. [55] As IPF is most typically diagnosed within the aged, senescence on each the organism and cellular levels are a unit of connection. Population studies have incontestable associate degree multiplied incidence and prevalence of IPF with older age, [56]

Diabetes Mellitus:
In a systematic review, Klein, et al known seven cross-sectional studies between 1975 associate degreed 2009 that reported an association between DM and indices of restriction (forced diagnostic test, FVC and diffusion capability of the respiratory organ for monoxide, DLCO) on pulmonary function testing. [57] the most theory concerning the mechanism by that DM is also a risk issue for IPF relates to hyperglycemia-mediated production of advanced glycosylation finish merchandise resulting in aerophilous injury and sequent over expression of pro-fibrotic cytokines, formative cell proliferation, and extracellular matrix deposition. [58]

Cigarette Smoke:
A history of smoke, whether or not current or former is over represented in IPF, with prevalence starting from 41–83%. [59] A study of families with IPF additionally found that a history of smoking cigarettes was related to the event of familial respiratory disease. [60] Smoke exposure encompasses a myriad of effects within the respiratory organ that area unit related to the event of IPF. Alveolar epithelial cells exposed to smoke in vitro over specific genes related to epithelial-to-mesenchymal transition and acquire a fibroblast-like constitution. [61]

Environmental Exposures:
Certain activity and environmental exposures have additionally been related to IPF. During a meta-analysis of six case-control studies, wood dust, metal dust, stone/sand, agricultural/farming, and ethereal were all considerably additional probably in IPF cases versus controls. Analysis of autopsy results from the UK and Japan has reported higher odds of death from IPF among metal employees. One study in Northern Italy has steered associate degree multiplied risk of incident IPF in association with pollution, though the findings failed to come through applied mathematics significance. [62]

Conclusion:
Study of families with IPF additionally found that a history of smoking cigarettes was related to the event of familial respiratory disease. Smoke exposure encompasses a myriad of effects within the respiratory organ that area unit related to the event of IPF. Certain activity and environmental exposures have additionally been related to IPF. During a meta-analysis of six case-control studies, wood dust, metal dust, stone/sand, agricultural/farming, and ethereal were all considerably additional probably. Therapeutic strategies must target specific aberrant pathways during the natural history of the pathogenesis of pulmonary fibrosis. Only when these issues are in place will we be able to improve the prognosis of disorders associated with progressive pulmonary fibrosis.

References:

(1) Lekhansh Shukla, Deepak S Ghadigaonkar, Pratima Murthy. Poisoning with Drugs of Abuse: Identification and Management. Indian J Crit Care Med 2019;23(Suppl 4):S296–S304.
(2) Eman Abdel Monem Abdel Rasheed, Nashwa Elmahdy, Ezzeldin Shalab et al. A Study of Pharmaceutical Drugs Poisoning Cases Admitted to the National Poisoning Center, Kasralainy Teaching Hospital in Cairo.Eurasian J Emerg Med. 2020;19(1): 10-5.
(3) David A. Zisman, Michael P. Keane, John A. Belperio, Robert M. Strieter, and Joseph P. Lynch, III. Pulmonary Fibrosis. Fibrosis Research. Vol 117.Page 3to 44.
(4) Paul W. Noble, Christina E. Barkauskas, Dianhua Jiang. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012; 122(8):2756–2762.
(5) Wim A. Wuyts, Carlo Agostini, Katerina M. Antoniouet et al.The pathogenesis of pulmonary fibrosis: a moving target.Eur Respir J 2013; 41: 1207–1218.
(6) MS Wilson and TA Wynn. Pulmonary fibrosis: pathogenesis, etiology and regulation.Mucosal Immunol. 2009 March; 2(2): 103–121.
(7) George A. Margaritopoulos, Eliza Tsitoura, Nikos Tzanakis et al. Self-Eating: Friend or Foe? The Emerging Role of Autophagy in Idiopathic Pulmonary Fibrosis.Hindawi Publishing Corporation Bio Med Research International Volume 2013, Article ID 420497, 8 pages.
(8) Toby M. Maher, and Mary E. Strek .Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treatMaher and Strek Respiratory Research (2019) 20:205 Pg 1 to 9.
(9) Jürgen Behr, Michael Kreuter, Marius M. Hoeper et al, Management of patients with idiopathic fibrosis in clinical practice: the Insights-IPF registry.Eur Respire J 2015; 46: 186–196.
(10) Daniel S. Glass, David Grossfeld, Heather A. Renna et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022; 16:84–96.
(11) Or Kalchiem Dekel , Jeffrey R. Galvin , Allen P. Burke et al , Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. J. Clin. Med. 2018, 7, 476 pg 1 to 27.
(12) S J Bourke.Interstitial lung disease: progress and problems Postgrad Med J 2006; 82:494–499.
(13) Carla R. Copeland and Lisa H. Lancaster. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD).Front. Med.2021; 8:743977.Pg 1 to 5.
(14) Eric S. White, Matthew Thomas , Susanne Stowasser et al.Challenges for Clinical Drug Development in Pulmonary Fibrosis. Front. Pharmacol.2022; 13:823085. Pg 1 to 9.
(15) Sharif R. Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. Am J Manag Care. 2017 Jul; 23(11 Suppl):S176-S182.
(16) J. M. Oldham, S. F. Ma, F. J. Martinez et al., "TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis, Am J Respir Crit Care Med Vol 192, Iss 12, pp 1475–1482, Dec 15, 2015.
(17) Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017 May 13; 389(10082):1941-1952
18) Qi Wu , Ke-jia Zhang , Shi-min Jiang et al, p53: A Key Protein That Regulates Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity Volume 2020, 13 pages. Published 30 Nov 2020.
(19)Bringardner, B.D., C.P. Baran, T.D. Eubank, and C.B. Marsh. . The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008 February; 10(2): 287–301.
(20) Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157(1):199–203.
(21) Siwik, D.A., D.L. Chang, and W.S. Colucci. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86:1259–1265.
22) Thomas A. Wynn. Integrating mechanisms of pulmonary fibrosis'. J Exp Med. 2011 Jul 4; 208(7):1339-50
(23) Keith C Meyer. Pulmonary fibrosis,part1: epideminology pathogenesis and diagnosis . Expert Rev Respir Med. 2017 May; 11(5):343-359.
(24) Ushakumary M. G., Riccetti M., and Perl, A. T. Resident Interstitial Lung Fibroblasts and Their Role in Alveolar Stem Cell Niche Development, Homeostasis, Injury, and Regeneration.Stem Cells Transl Med.2021;10,1021–1032.
(25) Keogh, B. A., and Crystal, R. G. Alveolitis: the Key to the Interstitial Lung Disorders. Thorax. 1982 Jan ;37(1);1–10.
(26) Selman, M., T.E. King, and A. Pardo. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-151.
(27) G.Bagnato, S. Harari, Cellular Interactions in the Pathogenesis of Interstitial Lung Diseases.Eur Respir Rev 2015 Mar; 24(135): 102–114.
(28) Romei C, Martini C. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochem Pharmacol.2021 Nov;193:114812.
(29) Nevins W Todd, Irina G Luzina, and Sergei P Atamas, Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012 Jul 23; 5(1):11.
(30) Saiman L. Microbiology of early CF lung disease. Paediatr Respire Rev 2004; 5 Suppl A:S367–9.
(31) Naoki Inui,,Satoshi Sakai and Masatoshi Kitagawa,Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway.Int. J. Mol Sci. 2021 Jun 5, 22(11), 6107.
(32) Laurent G. J. Harrison N. K. and McAnulty R. J. The regulation of collagen production in normal lung and during interstitial lung disease. Postgrad Med J. 1988; 64 Suppl 4:26-34.

(33) Ademola S. Ojo, Simon A. Balogun, Oyeronke T. Williams, and Olusegun S. Ojo4. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies.Pulm Med. 2020 Aug 10; 2020:6175964.
(34) Richard P. Marshall, Robin J. Mcanulty, Geoffrey J. Laurent. The Pathogenesis of Pulmonary Fibrosis: is there a Fibrosis Gene? Int J Biochem Cell Biol. 1997 Jan; 29(1):107-20.
(35) M. Demedts, U. Costabel. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias Eur Respir J 2002; 19: 794–796.
(36) Paul D. Bozyk and Bethany B. Moore,. Prostaglandin E and the Pathogenesis of Pulmonary Fibrosis.Am J Respir Cell Mol Biol. 2011 Sep;45(3):445-52.
(37) Michael Kreuter, Ulf Müller-Ladner, Ulrich Costabel et al, The Diagnosis and Treatment of Pulmonary Fibrosis.Dtsch Arztebl Int .2021 Mar 5; 118: 152–62.
(38) Peter M George, Athol U Wells, R Gisli Jenkins.Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapyLancet Respir Med 2020; 8: 807–15
(39) Hong-Meng Chuang, Tina Emily Shih, Kang-Yun Lu et al. Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination.Cell Transplant. 2018 Nov; 27(11) 1581–1587.
(40) M. Eddleston,, M.F. Wilks And N.A. Buckley,Prospects for treatment of paraquat-induced lung fibrosis with immunosuppressive drugs and the need for better prediction of outcome: a systematic review .QJM. 2003 November; 96(11): 809–824.
(41) Peter M George, Caroline M Patterson, Anna K Reed, Muhunthan Thillai.Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019 Mar; 7(3):271-282.
(42) Rosalía Laporta Hernandez , Myriam Aguilar Perez, María Teresa Lázaro Carrasco and Piedad Ussetti Gil. Lung Transplantation in Idiopathic Pulmonary Fibrosis.Med Sci . 2018 Aug 23; 6(3):68.

(43) David Weill.Lung transplantation: indications and contraindications. Journal of Thoracic Disease.2018 ; 10(7):4574-4587.
(44) Talmadge E King Jr, Annie Pardo, Moisés Selman.Idiopathic pulmonary fibrosis.Lancet. 2011 Dec 3; 378(9807):1949-61.
(45) Ganesh Raghu, Derek Weycker, John Edelsberg et al, Incidence and Prevalence of Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2006 Oct 1; 174(7):810-6.
(46) Luba Nalysnyk, Javier Cid-Ruzafa, Philip Rotella and Dirk Esser".Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.Eur Respir Rev. 2012 Dec 1; 21(126):355-61.
(47) Ganesh Raghu, Shih-Yin Chen, Qiang Hou et al, Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old.Eur Respir J 2016 Jul; 48 (1): 179–186.
(48) Jo HE, Glaspole I, Grainge C et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J 2017 Feb23; 49(2):1601592.
(49) Redente EF, Jacobsen KM, Solomon JJ et al, Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 2011 Oct, 301(4):L510–518.
(50) Voltz JW, Card JW, Carey MA et al, Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2008, 39(1):45–52.
(51)Lekgabe ED, Royce SG, Hewitson TD et al. The effects of relaxin and estrogen deficiency on collagen deposition and hypertrophy of nonreproductive organs. Endocrinology 2006, 147(12):5575–5583.
(52)Kropski JA, Blackwell TS, Loyd JE: The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J 2015, 45(6):1717–1727.
(53)Noth I, Zhang Y, Ma SF et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013, 1(4):309–317.
(54)Peljto AL, Zhang Y, Fingerlin TE et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA.2013 Jun 5;309(21):2232–2239.
(55)Alvarez D, Cardenes N, Sellares J et al : IPF lung fibroblasts have a senescent phenotype. Am J Physiol Lung Cell Mol Physiol 2017, 313(6):L1164–L1173.
(56)Raghu G, Weycker D, Edelsberg J et al : Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(7):810–816.
(57)Klein OL, Krishnan JA, Glick S et al : Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010, 27(9):977–987.
(58)Yang J, Xue Q, Miao L et al : Pulmonary fibrosis: a possible diabetic complication. Diabetes Metab Res Rev 2011, 27(4):311–317.
(59) Oh CK, Murray LA, Molfino NA: Smoking and idiopathic pulmonary fibrosis. Pulmonary Medicine Volume 2012:808260. Page 13
(60) Steele MP, Speer MC, Loyd JE et al: Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005, 172(9):1146–1152.
(61)Checa M, Hagood JS, Velazquez-Cruz R et al: Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells. PLoS One 2016, 11(3):e0150383
(62) Tanzira Zaman, Joyce S. Lee.Risk factors for the development of idiopathic pulmonary fibrosis: A review.Curr Pulmonol Rep. 2018 Dec; 7(4): 118–125.